Published in Clin Pharmacokinet on January 01, 2009
Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. Pharmacogenomics J (2015) 0.82
Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation. Int J Mol Sci (2015) 0.80
Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II. Clin Pharmacokinet (2016) 0.75
P70S6 kinase phosphorylation: a new site to assess pharmacodynamy of sirolimus. Chin Med J (Engl) (2015) 0.75
Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I. Clin Pharmacokinet (2016) 0.75
Immunosuppression Drug Therapy in Lung Transplantation for Cystic Fibrosis. Paediatr Drugs (2017) 0.75
Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med (2003) 7.51
Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm (1981) 6.53
Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant (2002) 5.49
Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med (2003) 3.61
Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med (1995) 3.11
Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet (2004) 2.58
Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant (2007) 2.55
Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet (1998) 2.42
A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation (1999) 2.27
Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am J Transplant (2004) 2.09
Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report--2007. J Heart Lung Transplant (2007) 2.03
A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation (1998) 1.97
Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet (2007) 1.79
Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet (2006) 1.78
Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant (2004) 1.77
Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant (2007) 1.76
Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation (2002) 1.64
Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation (2001) 1.62
Clinical pharmacokinetics of everolimus. Clin Pharmacokinet (2004) 1.56
Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit (2001) 1.53
Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Ther Drug Monit (2005) 1.44
Benefit of Neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction. Transplantation (2008) 1.44
The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther (1998) 1.42
Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet (2001) 1.36
Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit (2006) 1.30
Immunosuppression: practice and trends. Am J Transplant (2004) 1.28
Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther (2002) 1.20
Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation (1999) 1.17
Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol (1999) 1.16
Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation (2008) 1.16
Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos (2004) 1.15
OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics. Br J Clin Pharmacol (1982) 1.15
Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit (1999) 1.15
Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int (2002) 1.14
Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol (2001) 1.13
Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol (1997) 1.12
Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther (2004) 1.12
Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation (2004) 1.10
CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther (2004) 1.10
IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther (2007) 1.07
Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. Ther Drug Monit (2004) 1.06
Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther (2008) 1.05
Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin Pharmacokinet (2004) 1.05
Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. Transplant Proc (1998) 1.05
Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther (1993) 1.05
Registry of the International Society for Heart and Lung Transplantation: tenth official pediatric lung and heart/lung transplantation report--2007. J Heart Lung Transplant (2007) 1.04
Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit (2005) 1.04
Exposure-response relationships and drug interactions of sirolimus. AAPS J (2004) 1.03
C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. BioDrugs (2001) 1.03
Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation (2003) 1.01
Gastroparesis after combined heart and lung transplantation. J Clin Gastroenterol (2002) 1.01
40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med (2001) 1.01
A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin Pharmacokinet (2005) 1.01
Overview of tacrolimus-based immunosuppression after heart or lung transplantation. J Heart Lung Transplant (2005) 1.00
Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring. Ther Drug Monit (1995) 0.98
Pharmacokinetics of mycophenolate mofetil and sirolimus in children. Ther Drug Monit (2008) 0.98
Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms. Ther Drug Monit (2001) 0.97
Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant (2005) 0.97
Immunosuppressive therapy after human lung transplantation. Eur Respir J (2004) 0.96
Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol Dial Transplant (1999) 0.96
The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation (1999) 0.96
Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit (2002) 0.95
Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Transplantation (2001) 0.95
Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant (1998) 0.94
The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J Clin Pharmacol (1999) 0.94
Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int (2006) 0.94
Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit (2004) 0.94
Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue. Proteomics (2004) 0.93
Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation (1999) 0.92
Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant (2002) 0.92
Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation (1995) 0.91
Mycophenolic acid plasma concentrations: influence of comedication. Ther Drug Monit (2001) 0.91
Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther (2001) 0.91
Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem (2001) 0.90
Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? Transplantation (2004) 0.90
Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. Clin Pharmacokinet (2006) 0.89
Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J Am Soc Nephrol (2001) 0.88
Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant (2006) 0.87
Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies. Clin Pharmacokinet (2005) 0.87
Factors affecting oral cyclosporin disposition after heart transplantation: bootstrap validation of a population pharmacokinetic model. Eur J Clin Pharmacol (2000) 0.87
Post-surgical and obstructive gastroparesis. Curr Gastroenterol Rep (2007) 0.86
Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant (2005) 0.86
Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients. Clin Chem (2001) 0.86
Application of a gamma model of absorption to oral cyclosporin. Clin Pharmacokinet (2001) 0.86
Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients. J Heart Lung Transplant (2006) 0.86
Everolimus in pediatric de nova renal transplant patients. Transplantation (2003) 0.85
Lack of correlation between MMF dose and MPA level in pediatric and young adult cardiac transplant patients: does the MPA level matter? Am J Transplant (2004) 0.85
Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart Lung Transplant (2007) 0.85
Sirolimus: the evidence for clinical pharmacokinetic monitoring. Clin Pharmacokinet (2005) 0.84
Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant (2008) 0.84
Mycophenolate mofetil dose reduction for gastrointestinal intolerance is associated with increased rates of rejection in heart transplant patients. J Heart Lung Transplant (2008) 0.84
Altered pharmacokinetics of cyclosporin in heart-lung transplant recipients with cystic fibrosis. Ther Drug Monit (1990) 0.84
Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships. J Heart Lung Transplant (2006) 0.83
Immunosuppression for lung transplantation: evidence to date. Drugs (2007) 0.83
Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin Pharmacokinet (2002) 0.83
Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem (1999) 0.83
Cross-correlation of cyclosporine concentrations and biochemical measures of kidney and liver function in heart and heart-lung transplant recipients. Clin Chem (1990) 0.83
Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant (2001) 0.83
Pharmacokinetic validation of neoral absorption profiling. Transplant Proc (2000) 0.82
Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions. Transplantation (2003) 0.82
Measurement of the integral refractive index and dynamic cell morphometry of living cells with digital holographic microscopy. Opt Express (2005) 2.40
Cell refractive index tomography by digital holographic microscopy. Opt Lett (2006) 2.19
Living specimen tomography by digital holographic microscopy: morphometry of testate amoeba. Opt Express (2006) 1.94
Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum (2010) 1.75
Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit (2009) 1.68
Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychother Psychosom (2014) 1.64
Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology (2008) 1.62
Simultaneous cell morphometry and refractive index measurement with dual-wavelength digital holographic microscopy and dye-enhanced dispersion of perfusion medium. Opt Lett (2008) 1.53
Automated segmentation of multiple red blood cells with digital holographic microscopy. J Biomed Opt (2013) 1.47
Early cell death detection with digital holographic microscopy. PLoS One (2012) 1.35
In vivo endoscopic tissue diagnostics based on spectroscopic absorption, scattering, and phase function properties. J Biomed Opt (2003) 1.34
Noninvasive characterization of the fission yeast cell cycle by monitoring dry mass with digital holographic microscopy. J Biomed Opt (2009) 1.26
Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet (2009) 1.21
Comparative study of human erythrocytes by digital holographic microscopy, confocal microscopy, and impedance volume analyzer. Cytometry A (2008) 1.20
Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos (2004) 1.15
CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther (2006) 1.11
CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther (2004) 1.10
In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos (2005) 1.08
Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin Pharmacokinet (2004) 1.05
Numerical parametric lens for shifting, magnification, and complete aberration compensation in digital holographic microscopy. J Opt Soc Am A Opt Image Sci Vis (2006) 1.04
Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit (2005) 1.04
A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin Pharmacokinet (2005) 1.01
Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant Rev (Orlando) (2010) 1.00
Determination of transmembrane water fluxes in neurons elicited by glutamate ionotropic receptors and by the cotransporters KCC2 and NKCC1: a digital holographic microscopy study. J Neurosci (2011) 1.00
Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol (2011) 1.00
Automatic procedure for aberration compensation in digital holographic microscopy and applications to specimen shape compensation. Appl Opt (2006) 0.99
Mechanisms underlying postmortem redistribution of drugs: a review. J Anal Toxicol (2003) 0.98
Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos (2010) 0.98
Cell morphology and intracellular ionic homeostasis explored with a multimodal approach combining epifluorescence and digital holographic microscopy. J Biophotonics (2010) 0.97
Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients. Pharmacogenet Genomics (2012) 0.97
Submicrometer tomography of cells by multiple-wavelength digital holographic microscopy in reflection. Opt Lett (2009) 0.97
Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet (2010) 0.96
Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation. Ther Drug Monit (2010) 0.96
Polarization microscopy by use of digital holography: application to optical-fiber birefringence measurements. Appl Opt (2005) 0.96
Label-free second-harmonic phase imaging of biological specimen by digital holographic microscopy. Opt Lett (2010) 0.95
Spatial analysis of erythrocyte membrane fluctuations by digital holographic microscopy. Blood Cells Mol Dis (2009) 0.94
Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. Clin Pharmacokinet (2009) 0.94
Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol (2002) 0.94
Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit (2004) 0.94
Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. Drug Metab Dispos (2006) 0.93
Pesticide contamination of workers in vineyards in France. J Expo Sci Environ Epidemiol (2006) 0.93
Total aberrations compensation in digital holographic microscopy with a reference conjugated hologram. Opt Express (2006) 0.93
Screening of drugs and toxic compounds with liquid chromatography-linear ion trap tandem mass spectrometry. Clin Chem (2006) 0.91
Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. Ther Drug Monit (2004) 0.90
Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genomics (2007) 0.90
Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation. Clin Pharmacokinet (2009) 0.90
Real-time dual-wavelength digital holographic microscopy with a single hologram acquisition. Opt Express (2007) 0.90
Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies. Clin Pharmacokinet (2008) 0.89
Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. Clin Pharmacokinet (2006) 0.89
Characterization of microlenses by digital holographic microscopy. Appl Opt (2006) 0.88
A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits. Nephrol Dial Transplant (2010) 0.88
A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. Br J Clin Pharmacol (2006) 0.88
General unknown screening procedure for the characterization of human drug metabolites in forensic toxicology: applications and constraints. J Sep Sci (2009) 0.87
LC-MS/MS systematic toxicological analysis: comparison of MS/MS spectra obtained with different instruments and settings. Clin Biochem (2005) 0.87
Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies. Clin Pharmacokinet (2005) 0.87
Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse. Drug Metab Dispos (2012) 0.87
Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. Ther Drug Monit (2016) 0.86
Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment. Dig Liver Dis (2011) 0.86
Recognition and classification of red blood cells using digital holographic microscopy and data clustering with discriminant analysis. J Opt Soc Am A Opt Image Sci Vis (2011) 0.86
Label-free cytotoxicity screening assay by digital holographic microscopy. Assay Drug Dev Technol (2012) 0.86
Time-domain optical coherence tomography with digital holographic microscopy. Appl Opt (2005) 0.86
Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma. Clin Pharmacokinet (2002) 0.86
Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele. Br J Clin Pharmacol (2010) 0.86
Effect of mycophenolate acyl-glucuronide on human recombinant type 2 inosine monophosphate dehydrogenase. Clin Chem (2009) 0.85
Automated statistical quantification of three-dimensional morphology and mean corpuscular hemoglobin of multiple red blood cells. Opt Express (2012) 0.85
Current role of LC-MS in therapeutic drug monitoring. Anal Bioanal Chem (2007) 0.85
Automated quantitative analysis of 3D morphology and mean corpuscular hemoglobin in human red blood cells stored in different periods. Opt Express (2013) 0.85
Pitfalls and prevention strategies for liquid chromatography-tandem mass spectrometry in the selected reaction-monitoring mode for drug analysis. Clin Chem (2008) 0.85
Multisite analytical evaluation of the Abbott ARCHITECT cyclosporine assay. Ther Drug Monit (2010) 0.84
Effects of hypotonic stress and ouabain on the apparent diffusion coefficient of water at cellular and tissue levels in Aplysia. NMR Biomed (2014) 0.84
Submicrometer optical tomography by multiple-wavelength digital holographic microscopy. Appl Opt (2006) 0.84
Physical interpretation of the phase function related parameter γ studied with a fractal distribution of spherical scatterers. Opt Express (2010) 0.84
Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. Clin Pharmacokinet (2006) 0.84
Determination of mycophenolic acid plasma levels in renal transplant recipients co-administered sirolimus: comparison of an enzyme multiplied immunoassay technique (EMIT) and liquid chromatography-tandem mass spectrometry. Ther Drug Monit (2006) 0.83
Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters. Xenobiotica (2011) 0.83
Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients. Ther Drug Monit (2011) 0.83
Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. Clin Pharmacokinet (2012) 0.83
Influence of shot noise on phase measurement accuracy in digital holographic microscopy. Opt Express (2007) 0.83
Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure. Ther Drug Monit (2013) 0.83
High b-value diffusion-weighted imaging: a sensitive method to reveal white matter differences in schizophrenia. Psychiatry Res (2012) 0.83
Polarization imaging by use of digital holography. Appl Opt (2002) 0.83
Digital holographic microscopy applied to life sciences. Conf Proc IEEE Eng Med Biol Soc (2007) 0.83
Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients. Br J Clin Pharmacol (2014) 0.83
Spatially-resolved eigenmode decomposition of red blood cells membrane fluctuations questions the role of ATP in flickering. PLoS One (2012) 0.83
Simultaneous optical recording in multiple cells by digital holographic microscopy of chloride current associated to activation of the ligand-gated chloride channel GABA(A) receptor. PLoS One (2012) 0.82
Evaluation of an improved general unknown screening procedure using liquid chromatography-electrospray-mass spectrometry by comparison with gas chromatography and high-performance liquid-chromatography--diode array detection. J Am Soc Mass Spectrom (2003) 0.82
Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. Pharmacogenet Genomics (2010) 0.82
Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions. Transplantation (2003) 0.82
CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients. Transplantation (2011) 0.82
The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation. Expert Opin Drug Metab Toxicol (2011) 0.82
Post-mortem redistribution of three beta-blockers in the rabbit. Int J Legal Med (2005) 0.82
Purely numerical compensation for microscope objective phase curvature in digital holographic microscopy: influence of digital phase mask position. J Opt Soc Am A Opt Image Sci Vis (2006) 0.81
Feasibility of ribavirin therapeutic drug monitoring in hepatitis C. Ther Drug Monit (2009) 0.81
Shot-noise influence on the reconstructed phase image signal-to-noise ratio in digital holographic microscopy. Appl Opt (2006) 0.81
Quantitative phase restoration by direct inversion using the optical transfer function. Opt Lett (2011) 0.81
Identification of acepromazine in hair: an illustration of the difficulties encountered in investigating drug-facilitated crimes. J Forensic Sci (2008) 0.81
In vitro study of mycophenolic acid glucuronidation. Drug Metab Dispos (2004) 0.81
Measurement of absolute cell volume, osmotic membrane water permeability, and refractive index of transmembrane water and solute flux by digital holographic microscopy. J Biomed Opt (2013) 0.80
Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part II. Clin Pharmacokinet (2009) 0.80